Polycystic ovary syndrome
Conditions
Interventions
Observation group:None
Sponsors
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1.PCOS diagnosed with PCOS (clinical manifestations and/or biochemical changes of hyperandrogenism; menstrual abnormalities such as infrequent or anovulatory ovulation; ultrasound showing an ovarian volume =10 mL and/or =12 follicles with a diameter of 2–9 mm on the same section); 2.Aged between 18 and 40 years at enrollment; 3.No fertility needs in the recent period (6 months); 4.Based on the manifestations of hyperandrogenism, this study will include the same number of 4 groups of PCOS patients: Both clinical and biochemical hyperandrogenism; Only clinical hyperandrogenism;Only biochemical hyperandrogenism;Neither clinical nor biochemical hyperandrogenism. Clinical hyperandrogenism is defined as having the following symptoms and signs: acne, seborrheic dermatitis, androgenetic alopecia, hirsutism, acanthosis nigricans, etc. Biochemical hyperandrogenism is defined as relevant examination results within 6 months indicating hyperandrogenemia (such as elevated total testosterone, but not exceeding twice the normal level).
Exclusion criteria
Exclusion criteria: Metabolic abnormalities that significantly affect menstrual regulation or anti-androgen therapy, including diabetes, severe hypertension (systolic blood pressure =160 mmHg or diastolic blood pressure =100 mmHg) or vascular disease, hyperthyroidism, sex hormone-dependent tumors such as endometrial and breast cancer, liver disease or liver tumors, active cancer (metastatic, within 6 months of treatment or clinical remission), history of thrombosis or stroke, multiple risk factors for ischemic heart disease or atherosclerotic cardiovascular disease, complications of valvular heart disease, and systemic lupus erythematosus.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Preferences for attributes of drug treatment plans;Disease burden; | — |
Countries
China
Contacts
Public ContactDi Wen, Gu Zhuowei
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Outcome results
None listed